Drug companies Alkermes and Biogen have announced that Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), an oral...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
Drug companies Alkermes and Biogen have announced that Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for diroximel fumarate (BIIB098), an oral...
A recent study has found that multiple sclerosis (MS) patients,...
A one-year real world study of Rebif (interferon beta 1-a) has shown that relapsing remitting...
A debate on shared decision making in multiple sclerosis (MS) was led by a patient advocate and leading neurologists from the MS in the 21st Century Steering Group.
Chaired by...
The National Institute for Health and Care Excellence (NICE) are looking for people with multiple sclerosis (MS) or cancer who have personal experience of using cannabis-derived products for...
A recent Australian study has looked at a new potential treatment...
The US Food & Drugs Administration (FDA) has issued a...
Fampridine, also known as Fampyra, has once again been rejected by the...
Upper limb impairment is common in primary progressive multiple sclerosis (PPMS)....